Menu
Search
|

Menu

Close
X

Aveo Pharmaceuticals Inc AVEO.OQ (NASDAQ Stock Exchange Capital Market)

2.59 USD
-0.11 (-4.07%)
As of 4:00 PM EDT
chart
Previous Close 2.70
Open 2.70
Volume 441,375
3m Avg Volume 505,786
Today’s High 2.73
Today’s Low 2.51
52 Week High 3.64
52 Week Low 1.86
Shares Outstanding (mil) 121.50
Market Capitalization (mil) 351.12
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
8
FY16
3
FY15
19
EPS (USD)
FY18
-0.045
FY17
-0.611
FY16
-0.400
FY15
-0.280
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
57.05
6.55
Price to Book (MRQ)
vs sector
--
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
--
14.15
LT Debt to Equity (MRQ)
vs sector
--
11.31
Return on Investment (TTM)
vs sector
-183.57
12.83
Return on Equity (TTM)
vs sector
--
14.95

EXECUTIVE LEADERSHIP

Michael Bailey
President, Chief Executive Officer, Director, Since 2015
Salary: $361,611.00
Bonus: $81,001.00
Matthew Dallas
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Karuna Rubin
Senior Vice President, General Counsel, Since 2018
Salary: --
Bonus: --
Nikhil Mehta
Senior Vice President - Regulatory and Quality Assurance, Since 2017
Salary: --
Bonus: --
Mike Ferraresso
Vice President - Business Analytics and Commercial Operations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One Broadway, 14Th Floor
CAMBRIDGE   MA   02142

Phone: +1617.5312130

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

SPONSORED STORIES